Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Conditions

Multiple Sclerosis 2Carcinoma in Situ 2Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Interferon beta-1b × Clear all
NCT02486640 2023-07-24

BETAPREDICT

Bayer

Completed
162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡